Duragesic, Generics May Warrant Risk Management Plans, FDA Says

The agency will continue to monitor incidents of abuse or misuse of fentanyl transdermal systems and "may consider" requesting brand and generic manufacturers to implement a voluntary risk management plan, FDA says in denying citizen petition requests to delay approval of Duragesic generics.